FIELD: biotechnology.
SUBSTANCE: invention relates to an anti-EphA4 antibody, a method for production thereof, as well as a composition containing same. Also disclosed is an isolated nucleic acid coding said antibody, as well as a vector and a host cell containing said nucleic acid.
EFFECT: invention is effective for inhibiting phosphorylation of tau protein.
18 cl, 23 dwg, 3 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
